Trial Profile
A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK0594 in Patients With Overactive Bladder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 May 2021
Price :
$35
*
At a glance
- Drugs Serlopitant (Primary) ; Tolterodine
- Indications Overactive bladder
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Menlo Therapeutics; VYNE Therapeutics
- 12 Oct 2012 Planned number of patients 530 added as reported by EudraCT (EudraCT2005-006201-12).
- 12 Oct 2012 Planned number of patients 530 added as reported by EudraCT (EudraCT2005-006201-12).